USANA Health Sciences (NYSE:USNA) Issues FY 2024 Earnings Guidance

USANA Health Sciences (NYSE:USNA - Get Free Report) updated its FY 2024 earnings guidance on Tuesday. The company provided EPS guidance of 2.400-3.000 for the period, compared to the consensus EPS estimate of 2.720. The company issued revenue guidance of $850.0 million-$920.0 million, compared to the consensus revenue estimate of $889.8 million.

USANA Health Sciences Trading Down 3.4 %

USANA Health Sciences stock traded down $1.48 during trading hours on Tuesday, reaching $41.50. 104,538 shares of the company were exchanged, compared to its average volume of 80,488. USANA Health Sciences has a 12 month low of $41.45 and a 12 month high of $69.60. The stock has a 50-day moving average of $46.94 and a 200 day moving average of $48.56. The firm has a market cap of $798.46 million, a price-to-earnings ratio of 12.88, a PEG ratio of 1.33 and a beta of 0.91.

USANA Health Sciences (NYSE:USNA - Get Free Report) last released its quarterly earnings results on Tuesday, February 6th. The company reported $0.87 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.52 by $0.35. The company had revenue of $221.08 million during the quarter, compared to analysts' expectations of $206.70 million. USANA Health Sciences had a net margin of 6.93% and a return on equity of 13.49%. As a group, research analysts forecast that USANA Health Sciences will post 2.73 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on USNA shares. DA Davidson decreased their target price on shares of USANA Health Sciences from $53.00 to $48.00 and set a neutral rating on the stock in a research report on Thursday, February 22nd. StockNews.com upgraded USANA Health Sciences from a buy rating to a strong-buy rating in a research note on Friday, January 12th.

Insider Activity

In other news, insider Robert A. Sinnott sold 3,945 shares of the business's stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $46.55, for a total value of $183,639.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other USANA Health Sciences news, insider Robert A. Sinnott sold 3,945 shares of USANA Health Sciences stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $46.55, for a total value of $183,639.75. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David Mulham Mulham sold 4,311 shares of the stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $47.76, for a total transaction of $205,893.36. Following the sale, the insider now directly owns 7,825 shares of the company's stock, valued at approximately $373,722. The disclosure for this sale can be found here. In the last quarter, insiders have sold 24,807 shares of company stock valued at $1,200,791. 0.33% of the stock is currently owned by insiders.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.